A role for interleukin-17A in modulating intracellular survival of Mycobacterium bovis bacillus Calmette-Guérin in murine macrophages

Immunology

Volumn 140, Issue 3, 2013, Pages 323-334

  Ling, Wai Lim ^a   Wang, Liang Jie ^a   Pong, John C H ^a   Lau, Allan S Y ^a   Li, James C B ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Innate immunity; Nitric oxide; Tuberculosis

Indexed keywords

CHEMOKINE; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME PHOSPHORYLATION; GRANULOMA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; MACROPHAGE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL;

INNATE IMMUNITY; NITRIC OXIDE; TUBERCULOSIS;

ANIMALS; ANTHRACENES; BACTERIAL LOAD; CELL LINE; CELL SURVIVAL; HUMANS; INTERLEUKIN-17; INTRACELLULAR SPACE; MACROPHAGES; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MYCOBACTERIUM BOVIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; TUBERCULOSIS;

EID: 84884942763     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12140     Document Type: Article

References (57)

1. Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmcol Sci 2011; 32:601-6.
2. Rodrigues LC, Mangtani P, Abubakar I. How does the level of BCG vaccine protection against tuberculosis fall over time? BMJ 2011; 343:5974.
3. Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8:97-111.
4. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129:311-21.
5. Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011; 34:8-16.
6. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010; 21:455-62.
7. Okamoto Yoshida Y, Umemura M, Yahagi A et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184:4414-22.
8. Cruz A, Fraga AG, Fountain JJ et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207:1609-16.
9. Umemura M, Yahagi A, Hamada S et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guérin infection. J Immunol 2007; 178:3786-96.
10. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8:369-77.
11. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol 2004; 22:599-623.
12. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94:5243-8.
13. Flesch IE, Kaufmann SH. Mechanisms involved in mycobacterial growth inhibition by γ interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun 1991; 59:3213-8.
14. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-α controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001; 166:6728-34.
15. Chan ED, Morris KR, Belisle JT, Hill P, Remigio LK, Brennan PJ, Riches DW. Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-κB signaling pathways. Infect Immun 2001; 69:2001-10.
16. + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(MAPK) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001; 280:C441-50.
17. Roach TI, Barton CH, Chatterjee D, Liew FY, Blackwell JM. Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages. Immunology 1995; 85:106-13.
18. Flesch IE, Kaufmann SH. Activation of tuberculostatic macrophage functions by γ interferon, interleukin-4, and tumor necrosis factor. Infect Immun 1990; 58:2675-7.
19. Fang JW, Li JC, Au KY, Yim HC, Lau AS. Interleukin-17A differentially modulates BCG induction of cytokine production in human blood macrophages. J Leukoc Biol 2011; 90:333-41.
20. Chan MM, Cheung BK, Li JC, Chan LL, Lau AS. A role for glycogen synthase kinase-3 in antagonizing mycobacterial immune evasion by negatively regulating IL-10 induction. J Leukoc Biol 2009; 86:283-91.
21. Yim HC, Li JC, Pong JC, Lau AS. A role for c-Myc in regulating anti-mycobacterial responses. Proc Natl Acad Sci USA 2011; 108:17749-54.
22. Chan LL, Cheung BK, Li JC, Lau AS. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-γ-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol 2010; 88:303-11.
23. Cheung BK, Yim HC, Lee NC, Lau AS. A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1. BMC Immunol 2009; 10:64-73.
24. Darieva Z, Lasunskaia EB, Campos MN, Kipnis TL, Da Silva WD. Activation of phosphatidylinositol 3-kinase and c-Jun-N-terminal kinase cascades enhances NF-κB-dependent gene transcription in BCG-stimulated macrophages through promotion of p65/p300 binding. J Leukoc Biol 2004; 75:689-97.
25. Bennett BL, Sasaki DT, Murray BW et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98:13681-6.
26. 2-terminal kinase activation. J Pharmacol Exp Ther 2005; 315:1188-95.
27. Korhonen R, Linker K, Pautz A, Forstermann U, Moilanen E, Kleinert H. Post-transcriptional regulation of human inducible nitric-oxide synthase expression by the Jun N-terminal kinase. Mol Pharmacol 2007; 71:1427-34.
28. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004; 75:639-53.
29. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-16.
30. Cheung BK, Lee DC, Li JC, Lau YL, Lau AS. A role for double-stranded RNA-activated protein kinase PKR in Mycobacterium-induced cytokine expression. J Immunol 2005; 175:7218-25.
31. Wang L, Yang CL, Or TC, Chen G, Zhou J, Li JC, Lau AS. Differential effects of Radix Paeoniae Rubra (Chishao) on cytokine and chemokine expression inducible by mycobacteria. Chin Med 2011; 6:14-27.
32. Misko TP, Moore WM, Kasten TP et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233:119-25.
33. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175:1111-22.
34. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 1995; 63:736-40.
35. Weinberg JB, Misukonis MA, Shami PJ et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995; 86:1184-95.
36. Nicholson S, Bonecini-Almeida Mda G, Lapa e Silva JR et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996; 183:2293-302.
37. Nozaki Y, Hasegawa Y, Ichiyama S, Nakashima I, Shimokata K. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect Immun 1997; 65:3644-7.
38. Wang CH, Liu CY, Lin HC, Yu CT, Chung KF, Kuo HP. Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Eur Respir J 1998; 11:809-15.
39. Hickman-Davis JM, O'Reilly P, Davis IC, Peti-Peterdi J, Davis G, Young KR, Devlin RB, Matalon S. Killing of Klebsiella pneumoniae by human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2002; 282:944-56.
40. Weinberg JB. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 1998; 4:557-91.
41. Muhl H, Bachmann M, Pfeilschifter J. Inducible NO synthase and antibacterial host defence in times of Th17/Th22/T22 immunity. Cell Microbiol 2011; 13:340-8.
42. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, Suzumura A. Production and functions of IL-17 in microglia. J Neuroimmunol 2008; 194:54-61.
43. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 1998; 273:27467-73.
44. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997; 40:1050-3.
45. Jung SB, Yang CS, Lee JS et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun 2006; 74:2686-96.
46. Bhatt KH, Sodhi A, Chakraborty R. Role of mitogen-activated protein kinases in peptidoglycan-induced expression of inducible nitric oxide synthase and nitric oxide in mouse peritoneal macrophages: extracellular signal-related kinase, a negative regulator. Clin Vaccine Immunol 2011; 18:994-1001.
47. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22:240-73.
48. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103:239-52.
49. Kiemer AK, Muller C, Vollmar AM. Inhibition of LPS-induced nitric oxide and TNF-α production by α-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol Cell Biol 2002; 80:550-7.
50. Kristof AS, Marks-Konczalik J, Moss J. Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 2001; 276:8445-52.
51. Li JC, Au KY, Fang JW, Yim HC, Chow KH, Ho PL, Lau AS. HIV-1 trans-activator protein dysregulates IFN-γ signaling and contributes to the suppression of autophagy induction. AIDS 2011; 25:15-25.
52. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42.
53. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119:753-66.
54. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 2007; 27:135-44.
55. Herbst S, Schaible UE, Schneider BE. Interferon γ activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS ONE 2011; 6:e19105-12.
56. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from l-arginine. J Immunol 1990; 144:4794-7.
57. Vazquez-Torres A, Jones-Carson J, Mastroeni P, Ischiropoulos H, Fang FC. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on microbial killing by activated peritoneal macrophages in vitro. J Exp Med 2000; 192:227-36.